Evidence map›Paper›PMID 40101455›Full record

ArticleVaccine2025

Meeting report: CEPI workshop on Rift Valley fever epidemiology and modeling to inform human vaccine development, Nairobi, 4-5 June 2024.

Radhika Gharpure, Carolin Vegvari, Alemseged Abdissa, Yewande Alimi, Assaf Anyamba, Jochen Auerbach, Bernard Bett, Brian H Bird, Ndeye Sakha Bob, J Gabrielle Breugelmans and 45 more

Abstract readConference Proceedings
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

55 authors.

Radhika GharpureCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA. Electronic address: radhika.gharpure@cepi.net.
Carolin VegvariCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Alemseged AbdissaArmauer Hansen Research Institute, Addis Abeba, Ethiopia.
Yewande AlimiAfrica Centres for Disease Control and Prevention, Addis Ababa, Ethiopia.
Assaf AnyambaUniversity of Maryland Baltimore County and NASA Goddard Space Flight Center, Greenbelt, MD, USA.
Jochen AuerbachCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Bernard BettInternational Livestock Research Institute (ILRI), Nairobi, Kenya.
Brian H BirdSchool of Veterinary Medicine, University of California Davis, Davis, California, USA.
Ndeye Sakha BobInstitut Pasteur de Dakar, Senegal.
J Gabrielle BreugelmansCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Jessica ClarkSchool of Biodiversity, One Health and Veterinary Medicine, Univeristy of Glasgow, Glasgow, UK.
Sarah CleavelandSchool of Biodiversity, One Health and Veterinary Medicine, Univeristy of Glasgow, Glasgow, UK.
Jakob CramerCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Jeanette DawaCenter for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya.
Petra C FayThe Wellcome Trust, London, UK.
Pierre FormentyWorld Health Organization, Geneva, Switzerland.
Volker GerdtsVaccine and Infectious Disease Organization, University of Saskachewan, Saskatoon, Canada.
Keli N GerkenUniversity of Liverpool, Institute of Infection, Veterinary, and Ecological Sciences, Liverpool, UK.
John GitongaKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Martin GroschupFriedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald, Germany.
James HeighwayCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Sherry Ama Mawuko JohnsonSchool of Veterinary Medicine, University of Ghana, Accra, Ghana.
John JumaInternational Livestock Research Institute (ILRI), Nairobi, Kenya.
Rebekah C KadingColorado State University, Fort Collins, CO, USA.
Maureen KamauMpala Research Centre, Laikipia, Kenya.
Samuel KeramaPharmacy and Poisons Board, Nairobi, Kenya.
Baratang Alison LubisiARC: Onderstepoort Veterinary Institute, Pretoria, South Africa.
Julius LutwamaUganda Virus Research Institute, Entebbe, Uganda.
Dick LuyimbaziBunyavax, LARISSA II project, Lelystad, Netherlands.
Dadi MaramiHaramaya University, College of Health and Medical Sciences, Harar, Ethiopia.
Sean M MooreFogarty International Center, National Institutes of Health, Bethesda, MD, USA.
Mathew MuturiKenya Zoonotic Disease Unit, Nairobi, Kenya.
Grace MwangokaIfakara Health Institute, Ifakara, Tanzania.
Angela NdiuWashington State University Global Health Kenya, Nairobi, Kenya.
M Kariuki NjengaWashington State University Global Health Kenya, Nairobi, Kenya.
Richard NjouomCentre Pasteur du Cameroun, Yaounde, Cameroon.
Luke NyakarahukaMakerere University, Kampala, Uganda.
Serge NzietchuengFood and Agriculture Organization of the United Nations, Nairobi, Kenya.
Paul OlooCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Mark OtiendeKEMRI-Wellcome Trust Research Programme, Kilifi, Kenya.
Samuel OyolaInternational Livestock Research Institute (ILRI), Nairobi, Kenya.
Lodovico Samuele PaganiniSwissmedic, Swiss Agency for Therapeutic Products, Bern, Switzerland.
Pranav S PanditSchool of Veterinary Medicine, University of California Davis, Davis, California, USA.
Carine PuntBunyavax, LARISSA II project, Lelystad, Netherlands.
Abdallah M SamyMedical Ain Shams Research Institute (MASRI), Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Silvia SitumaWashington State University Global Health Kenya, Nairobi, Kenya.
Heidi SneddonCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA.
Quirine A Ten BoschWageningen University and Research, Wageningen, Netherlands.
Seda Tezcan-UlgerMersin University Faculty of Medicine, Mersin, Türkiye.
Peter N ThompsonUniversity of Pretoria, Pretoria, South Africa.
Mike TildesleyZeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, School of Life Sciences and Mathematics Institute, University of Warwick, Coventry, UK.
Bachirou TintoInstitit de recherche en sciences de la santé (IRSS), Ouagadougou, Burkina Faso.
Juan F VesgaUK Health Security Agency, London, UK.
Paul P Wichgers SchreurWageningen Bioveterinary Research, Lelystad, Netherlands.
Peter HartCoalition for Epidemic Preparedness Innovations, Oslo, Norway, London, UK, and Washington, DC, USA. Electronic address: peter.hart@cepi.net.

Funding

Zoonotic and Emerging Infectious Diseases Training ProgramD43TW011519 · FIC · WASHINGTON STATE UNIVERSITY · PI Walter Godfrey Jaoko, Thumbi Mwangi · 2020 to 2026
$1.2M
FIC NIH HHS D43 TW011519World Health Organization 001
6 · The paper itself

Abstract

Rift Valley fever (RVF) is a zoonotic viral disease that causes epidemics and epizootics among humans and livestock, resulting in substantial health and socioeconomic consequences. Currently, there are no RVF vaccines licensed for humans, but several candidates show promise in early-stage development. Existing gaps in RVF epidemiological data and challenges associated with predicting RVF outbreak risk complicate the planning of efficacy studies, making the pathway to licensure for promising candidates unclear. In June 2024, the Coalition for Epidemic Preparedness Innovations (CEPI) convened a two-day workshop in Nairobi, Kenya, to discuss RVF epidemiology, modeling priorities, and specific gaps relevant to human RVF vaccine development. The workshop included representatives from multiple RVF-endemic countries, key global collaborators, and international health organizations. Workshop participants identified five key priorities: (1) Looking beyond outbreaks: There is a need to better characterize the complex One Health epidemiology of RVF and understand interepidemic persistence of the virus; (2) Better data for better models: Epidemiological modeling is crucial for research, prediction, and planning, but it requires accurate and representative data; (3) New, improved and accessible diagnostics and serological assays: These are needed to inform epidemiology and case definitions, without which RVF research will continue to suffer due to paucity of data and challenges in determining infection and exposure; (4) Defining use cases, regulatory pathways, and implementation strategies for human vaccines: Clarity on these topics will facilitate licensure and effective use of RVF vaccines; and (5) People-centered approaches: Community engagement and involvement of social and behavioral scientists are key to the success of human vaccine research and development and implementation, particularly as the virus impacts livestock and livelihoods. Workshop participants welcomed a renewed focus for RVF epidemiology and modeling, and expressed enthusiasm for continued multidisciplinary collaborations to support enabling sciences for human RVF vaccine research and development.

Indexed as

Rift Valley FeverVaccine DevelopmentViral VaccinesAnimalsDisease OutbreaksHumansKenyaRift Valley fever virusZoonosesViral VaccinesResearch and developmentRift Valley feverVaccine development

Identifiers

PMID40101455
PMCPMC12132047

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.